Abivax (ABVX) Short-Term Debt repayments (2024 - 2026)
Abivax (ABVX) recorded quarterly Short-Term Debt repayments of -$482347.2 in Q1 2026, down 27.34% quarter-over-quarter from -$378773.8 in Q3 2025, and down 99.37% on a YoY basis from -$76.8 million in Q1 2025.
Abivax (ABVX) Short-Term Debt repayments (2024 - 2026) Analysis & Trends
Abivax's Short-Term Debt repayments history runs 3 years deep, the most recent figure standing at -$482347.2 for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 102,000.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -482,347.21 |
| 10 | Regeneron Pharmaceuticals | 66.09 Bn | 57.33 Bn | 3.31 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -482,347.21 |
| Mar 31, 2026 | -482,347.21 |
| Sep 30, 2025 | -378,773.85 |
| Sep 30, 2025 | -378,773.85 |
| Jun 30, 2025 | -258,086.81 |
| Jun 30, 2025 | -258,086.81 |
| Mar 31, 2025 | -241,933.42 |
| Mar 31, 2025 | -241,933.42 |
| Sep 30, 2024 | -138,375.66 |
| Sep 30, 2024 | -138,375.66 |
| Jun 30, 2024 | -144,302.94 |
| Jun 30, 2024 | -144,302.94 |
| Mar 31, 2024 | -155,349.73 |
| Mar 31, 2024 | -155,349.73 |